London close: Stocks finish firmer in subdued trading
13th Sep 2024 16:44
(Sharecast News) - London stocks closed in positive territory on Friday, bolstered by hopes of an interest rate cut in the United States, although the gains were modest as trading remained subdued.
Read moreLondon close: Stocks mixed on latest UK jobs data
10th Sep 2024 14:47
(Sharecast News) - London's stock markets closed with mixed results on Tuesday, as investors weighed the latest UK jobs data showing both a slowdown in pay growth and a decline in the unemployment rate.
Read moreAstraZeneca shares drop on lung cancer trial update
10th Sep 2024 09:54
(Sharecast News) - The share price of AstraZeneca took a big hit on Tuesday after investors reacted to disappointing news from the company's latest lung cancer trials.
Read moreLondon close: Stocks slip on relatively quiet Friday
16th Aug 2024 17:46
(Sharecast News) - London's stock markets closed lower on Friday, weighed down by a stronger pound and mixed investor sentiment following the release of the latest UK retail sales figures.
Read moreAstraZeneca's Imfinzi gets fresh approval in the US
16th Aug 2024 07:15
(Sharecast News) - AstraZeneca announced on Friday that the US Food and Drug Administration (FDA) has approved its drug durvalumab, branded Imfinzi, for the treatment of early-stage non-small cell lung cancer (NSCLC) in patients eligible for surgery.
Read moreAstraZeneca prices EUR 1.4bn eurobond offering
30th Jul 2024 11:56
(Sharecast News) - AstraZeneca announced on Tuesday that its wholly owned subsidiary, AstraZeneca Finance, priced a €1.4bn eurobond offering on 29 July.
Read moreLondon close: Stocks finish mixed at start of busy week
29th Jul 2024 15:35
(Sharecast News) - London stocks closed with mixed results on Monday, reflecting a cautious market sentiment ahead of a busy week of earnings reports and crucial policy announcements from major central banks on both sides of the Atlantic.
Read moreAstraZeneca reports positive results from leukaemia drug trial
29th Jul 2024 07:10
(Sharecast News) - AstraZeneca has hailed positive high-level results from a clinical trial of its Calquence treatment for adults with chronic lymphocytic leukaemia (CLL).
Read moreAstraZeneca gets positive feedback on possible Imfinzi indication
26th Jul 2024 09:15
(Sharecast News) - AstraZeneca's 'Imfinzi', or durvalumab, was recognised by the FDA's oncologic drugs advisory committee (ODAC) on Friday for its efficacy in treating resectable non-small cell lung cancer (NSCLC), based on phase three trial results.
Read moreLondon close: Stocks mixed on tsunami of updates, US GDP data
25th Jul 2024 15:27
(Sharecast News) - London stocks closed with mixed results on Thursday as investors processed faster-than-anticipated economic growth in the United States, following a heavy flow of corporate announcements earlier in the day.
Read moreAstraZeneca hikes full-year guidance after strong first half
25th Jul 2024 07:19
(Sharecast News) - AstraZeneca revised its full-year 2024 guidance upwards on Thursday, anticipating mid-teens percentage growth in both total revenue and core earnings per share at constant exchange rates.
Read moreAstraZeneca endometrial cancer treatment recommended for EU approval
1st Jul 2024 07:17
(Sharecast News) - AstraZeneca announced on Monday that 'Imfinzi', or durvalumab, and 'Lynparza', or olaparib, have received a recommendation for approval in the European Union (EU) as treatments for primary advanced or recurrent endometrial cancer in patients with specific genetic profiles.
Read moreAstraZeneca posts mixed results from recent Imfinzi trials
25th Jun 2024 07:17
(Sharecast News) - AstraZeneca announced contrasting results from two phase three trials involving its immunotherapy drug 'Imfinzi', or durvalumab, on Tuesday.
Read moreAstraZeneca trial fails to treat 'challenging' breast cancer
18th Jun 2024 07:17
(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.
Read moreAstraZeneca's Imfinzi gets US approval for endometrial cancer patients
17th Jun 2024 07:15
(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.
Read more